ADYEN:EURONEXT AMSTERDAM
Adyen NV
Data as of 2026-03-10 - not real-time
€956.90
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Adyen shares are trading at €956.9, sitting just below the 20‑day SMA of €964 and well under the 50‑day (€1,191) and 200‑day (€1,394) averages, signaling a short‑term bearish bias. The RSI of 38 hints at a modest oversold condition, while the MACD histogram is positive, offering a faint bullish signal amid decreasing volume and a high 30‑day volatility of 85%. Recent earnings‑call commentary noted a stock plunge despite solid revenue growth, adding to near‑term pressure around the support level of €890.7.
Fundamentally, Adyen boasts a 17% revenue growth rate, 68% gross margin, and a 49.5% operating margin, underscored by €10.8 bn of cash and minimal debt. Its forward PE of 20 is well below the industry average of 37, and the DCF‑derived fair value of €808 suggests the current price still carries a premium, though analysts project a median target of €1,511, implying significant upside. Strong cash generation, a 22% ROE, and a “strong‑buy” consensus reinforce a longer‑term growth narrative despite the present technical headwinds.
Fundamentally, Adyen boasts a 17% revenue growth rate, 68% gross margin, and a 49.5% operating margin, underscored by €10.8 bn of cash and minimal debt. Its forward PE of 20 is well below the industry average of 37, and the DCF‑derived fair value of €808 suggests the current price still carries a premium, though analysts project a median target of €1,511, implying significant upside. Strong cash generation, a 22% ROE, and a “strong‑buy” consensus reinforce a longer‑term growth narrative despite the present technical headwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages
- Decreasing trading volume
- Recent earnings‑call disappointment
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust revenue and margin expansion
- Attractive forward PE versus industry
- Strong cash position and low net debt
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Secular growth in global payments
- High ROE and consistent free cash flow
- Analyst consensus and significant upside to target prices
Key Metrics & Analysis
Financial Health
Revenue Growth16.90%
Profit Margin44.71%
P/E Ratio28.4
ROE22.33%
ROA5.92%
Debt/Equity4.78
P/B Ratio5.7
Op. Cash Flow€1.0B
Free Cash Flow€534.3M
Industry P/E36.8
Technical Analysis
TrendBearish
RSI38.3
Support€890.70
Resistance€1,234.00
MA 20€964.02
MA 50€1,190.91
MA 200€1,393.81
MACDBullish
VolumeDecreasing
Fear & Greed Index77.59
Valuation
Fair Value€807.83
Target Price€1,460.82
Upside/Downside52.66%
GradeFair
TypeGrowth
Risk Assessment
Beta0.46
Volatility85.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
More Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.